Fas splicing variants and their effect on apoptosis

Advances in Experimental Medicine and Biology

Volumn 406, Issue , 1996, Pages 125-134

  Ruberti, Giovina ^a   Cascino, Isabella ^a   Papoff, Giuliana ^a   Eramo, Adriana ^a  

^a CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; MESSENGER RNA;

ALTERNATIVE RNA SPLICING; APOPTOSIS; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0029909361     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4899-0274-0_13     Document Type: Review

References (67)

1. C.W.J. Smith, J. G. Patton, and B. Nadal-Ginard, Alternative splicing in the control of gene expression, Annu. Rev. Genet. 23:527 (1989).
2. P.M. Bingham, T. -B. Chou, I. Mims, and Z. Zachar, On/Off regulation of gene expression at the level of splicing. Trends Genet. 4:134 (1988).
3. L.R. Bell, E.M. Maine, P. Schedl, and T.W. Cline, Sex-lethal, a drosophila sex determination switch gene, inhibits sex-specific RNA splicing and sequence similarity to RNA binding proteins, Cell 55:1037 (1988).
4. R.T. Boggs, P. Gregor, S. Idriss, J.M. Belote, and M. Mc Keown, Regulation of sexual differentiation in D. melanogaster via alternative splicing of RNA frome the transformer gene, Cell 50:739 (1987).
5. C.A. Smith, T. Farrah, and R.G. Goodwin, The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 76:959 (1994).
6. S. Nagata, and P. Golstein, The Fas death factor, Science 267:1449 (1995).
7. P. Vandenabeele, W. Declercq, R. Beyaert, and W. Fiers, Two tumour necrosis factor receptors: structure and function, TIBS 5:392 (1995).
8. M.G. Cifone, R. De Maria, P. Roncaioli, M.R. Rippo, M. Azuma, L.L. Lanier, A. Santoni, R. and Testi, R, Apoptotic signaling through CD95 (Fas/Apo-1) activates and acidic sphingomyelinase, J. Exp. Med. 180:1547 (1994).
9. B.M. Gill, H. Nishikata, G. Chan, T.L. Delovitch, and A. Ochi, Fas antigen and shingomyelin-ceramide turnover-mediated signaling: role in life and death of T lymphocytes, Immunol. Rev. 142:113 (1995)
10. E. Gulbins, R. Bissonette, A. Mahboubi, S. Martin, W. Nishioka, T. Brunner, G. Baier, G. Baier-Bitterlich, C. Byrd, F. Lang, R. Kolesnick, A. Altman, and D. Green, Fas-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway, Immunity 2:341 (1995).
11. C. Tepper, S. Jayadev, B. Liu, A. Bielawska, R. Wolff, S. Yonehara, Y.A. Hannun, and M.F. Seldin, Role of ceramide as an endogenous mediator of Fas-induced cytotoxicity, Proc. Natl. Acad. Sci. USA 92:8443 (1995).
12. M.G. Cifone, P. Roncaioli, R. De Maria, G. Camarda, A. Santoni, G. Ruberti, and R. Testi, Multiple pathways originate at the Fas/Apo-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal, EMBO J. 14:5859 (1995).
13. M.R. Alderson, R.J. Armitage, E. Maraskowsky, T.W. Tough, E. Roux, K. Schooley, F. Ramsdell, and D.H. Lynch, Fas transduces activation signals in normal human T lymphocytes, J. Exp. Med. 178: 2231 (1993).
14. R.A. Heller, and M. Kronke, Tumor necrosis factor-mediated signaling pathways, J. Cell Biol. 126:5 (1994).
15. J. Cheng, T. Zhou, C. Liu, J.P. Shapiro, M.J. Brauer, M.C. Kiefer, P.J. Barr, and J.D. Mountz, Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759 (1994).
16. I. Cascino, G. Fiucci, G. Papoff, and G. Ruberti, Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing, J. Immunol. 154:2706 (1995).
17. G. Papoff, I. Cascino, A. Eramo, G. Starace, D.H. Lynch, and G. Ruberti, An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro, (submitted).
18. C. Liu, J. Cheng, and J.D. Mountz, Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation, Biochem. J. 310:957 (1995)
19. I. Behrmann, H. Walczak, and P.H. Krammer, Structure of the human APO-1 gene, Eur. J. Immunol. 24:3057 (1994).
20. J. Cheng, L. Changdan, W.J. Koopman, and J.D. Mountz, Characterization of the human Fas gene. Exon/Intron organization and promoter region, J. Immunol. 154:1239 (1995).
21. F. Rieux-Laucat, F. Le Deist, C. Hivroz, I.A.G. Roberts, K.M. Debatin, A. Fischer, and J.P. de Villartay, Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity, Science 268:1347 (1995).
22. G.H. Fisher, F.J. Rosenberg, S.E. Straus, J.K. Dale, L.A. Middelton, A.Y. Lin, W. Strober, M.J. Lenardo, J.M. and Puck, Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome, Cell 81:935 (1995).
23. N. Itoh, and S. Nagata, A novel protein domain required for apoptosis, J. Biol. Chem. 268:10932 (1993).
24. L.A. Tartaglia, T.M. Ayres, G.H.W. Wong, and D.V. Goeddel, A novel domain within the 55 Kd TNF receptor signals cell death, Cell 74:845 (1993).
25. N. Itoh, S. Yonehara, A. Ishii, M. Yonehara, S. Mizushima, M. Sameshima, A. Hase, Y. Seto, and S. Nagata, The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis, Cell 66:233 (1991).
26. M.R. Alderson, T.W. Tough, S. Braddy, T. Davis-Smith, E. Roux, K. Schooley, R.E. Miller, and D.H. Lynch, Regulation of apoptosis and T cell activation by Fas-specific monoclonal antibodies. Int. Immunol. 6:1799 (1994).
27. P.H. Krammer, et al., The role of APO-1 mediated apoptosis in the immune system, Immunol. Rev. 142:175 (1994).
28. L.B. Owen-Schaub, S. Yonehara, W.L. Crump, and E.A. Grimm, DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement, Cellular Immunol. 140:197 (1992).
29. C. Klas, K.-M. Debatin, R.R. Jonker, and P.H. Krammer, Activation interferes with the APO-1 patway in mature human T cells, Int. Immunol. 5:625 (1993).
30. A. Anel, M. Buferne, C. Boyer, A.-M. Schmitt-Verhulst, and P. Golstein, T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and Cyclosporin A, Eur. J. Immunol. 24:2469 (1994).
31. F. Vignaux, E. Vivier, B. Malissen, V. Depraetere, S. Nagata, and P. Golstein, TCR/CD3 coupling to Fas-based cytotoxicity, J. Exp. Med. 181:781 (1995).
32. J. Dhein, H. Walczak, C. Baumier, K.-M. Debatin, and P.H. Krammer, Autocrine T-cell suicide mediated by APO-1/(Fas/CD95), Nature 373: 438 (1995).
33. T. Brunner, R.J. Mogil, D. La Face, N.J. Yoo, A. Mahboubi, F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, C.F. Ware, and D.R.Green, Cell- autonomous Fas (CD95)/Fas-ligand interaction mediates activation- induced apoptosis in T cell hybridomas, Nature 373:441 (1995).
34. S.-T. Ju, D.J. Panka, H. Cui, R.M. Ettinger, D.H. El-Khatib, B. Sherr, Z. Stanger, and A. Marshak-Rothstein, Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation, Nature 373:444 (1995).
35. M.R. Alderson, T.W. Tough, T. Davis-Smith, S. Braddy, B. Falk, K.A. Schooley, R.G. Goodwin, C.A. Smith, F. Ramsdell, and D.H. Lynch, Fas ligand mediates activation-induced cell death in human T lymphocytes, J. Exp. Med. 181:71 (1995).
36. F. Leithauser, J. Dhein, G. Mechtersheimer, K. Koretz, S. Brunderlein, C. Henne, A. Schmidt, K.-M. Debatin, P.H. Krammer, and P. Moller, Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells, Lab. Invest. 69:415 (1993).
37. L.B. Owen-Schaub, R. Radinsky, E. Kruzel, K. Berry, and S. Yonehara, Anti-Fas mediated apoptosis in nonhematopoietic tumors: neither Fas/Apo-1 nor bcl-2 expression is predictive of biological responsiveness, Cancer Res 54:1580 (1994).
38. M.Y. Mapara, R. Bargou, C. Zugck, H. Dohner, F. Ustaoglu, R.R. Jonker, P.H. Krammer, and B. Dorken, APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression, Eur. J. Immunol. 23:702 (1993).
39. K.-M. Debatin, C.K. Goldman, T.A. Waldmann and P.H. Krammer, APO-1 induced apoptosis of leukemia cells from patients with adult T-cell leukemia, Blood 81:2972 (1993).
40. G. Natoli, A. Ianni, A. Costanzo, G. De Petrillo, I. Ilari, P. Chirillo, C. Balsano, and M. Levrero, Resistance to Fas-mediated apoptosis in human hepatoma cells, Oncogene 11:1157 (1995).
41. L.B. Owen-Schaub, L.S. Angelo, R. Radinsky, C.F. Ware, T.G. Gesner, and D.P. Bartos, Soluble Fas/Apo-1 in tumor cells: a potential regulator of apoptosis, Cancer Letters 94:1 (1995).
42. D.P.M. Hughes, and I.N. Crispe, A Naturally occurring soluble isoforms of murine Fas generated by alternative splicing, J. Exp. Med. 182:1395 (1995).
43. E. Knipping, K.-M. Debatin, K. Stricker, B. Heilig, A. Eder, and P.H. Krammer, Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias, Blood 85:1562 (1995).
44. N. Goel, D.T. Ulrich, E. St Clair, J.A. Fleming, D.H. Lynch, M.F. Seldin, Lack of correlation of serum soluble Fas levels and autoimmune disease, Arthritis Rheum. 38:1738 (1995).
45. R. A. Smith, and C. Baglioni, The active form of tumor necrosis factor is a trimer, J. Biol. Chem. 262:6951 (1987).
46. M.J. Eck, and S.R. Sprang, The structure of tumor necrosis factor at 2.6 A resolution, J. Biol. Chem. 264:17595 (1989).
47. E.Y. Jones, D.I. Stuart, and N.P.C. Walker, Structure of tumor necrosis factor, Nature 338:225 (1989).
48. M.J. Eck, M. Ultsch, E. Rinderknecht, A.M. deVos, and S.R. Spring, The structure of human lymphotoxin (tumor necrosis factor beta) at 1.9- A resolution, J. Biol. Chem. 267:2119 (1992).
49. D. Banner, A. D'Arcy, W. Janes, R. Gentz, H.-J. Schoenfeld, C. Broger, H. Loetscher, and W. Lesslauer, Crystal structure of the soluble human 55kd TNF receptor-human TNFβ complex: implications for TNF receptor activation, Cell 73:431 (1993).
50. S. Yonehara, A. Ishii, and M. Yonehara, A cell killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of TNF, J. Exp. Med. 169:1747 (1989).
51. M. Tanaka, T. Suda, T. Takahashi, and S. Nagata, Expression of the functional soluble form of human Fas ligand in activated lymphocytes, EMBO J. 14:1129 (1995).
52. A. Basu, M. Raghmath, S. Bishayee, and M. Das, Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation, Mol. Cell. Biol. 9:671 (1989).
53. L.M. Obeid, C.M. Linardic, L.A. Karolak, and Y.A. Hannun, Programmed cell death induced by ceramide, Science 259:1769 (1993).
54. I. Cascino, G. Papoff, R. De Maria, R. Testi, and G. Ruberti, Fas/Apo- 1/CD95 receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis, J. Immunol. 156:13 (1996).
55. S. Nagata, and T. Suda, Fas and Fas ligand: lpr and gld mutations, Immunol. Today 16:39 (1995).
56. A.M. Chinnaiyan, K. O'Rourke, M. Tewari, and V.M. Dixit, FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis, Cell 81:505 (1995).
57. M.P. Boldin, E.E. Varfolomeev, Z. Pancer, I.L. Mett, J.H. Camonis, and D. Wallach, A novel protein that interact with the death domain of Fas/Apo-1 contains a sequence motif related to the death domain, J. Biol. Chem. 270:7795 (1995).
58. H. Hsu, J. Xiong, and D.V. Goeddel, The TNF receptor 1-associated protein TRADD signals cell death and NF-kB activation, Cell 81:495 (1995).
59. B.Z. Stanger, P. Leder, T.-H. Lee, E. Kim, and B. Seed, RIP: a novel protein containing a death domain that interacts with Fas/Apo-1 (CD95) in Yeast and causes cell death, Cell 81:513 (1995).
60. K. White, M.E. Grether, J.M. Abrams, L. Young, K. Farrell, and H. Steller, Genetic control of programmed cell death in Drosophila, Science 264:677 (1994).
61. P. Golstein, D. Marguet, and V. Depraetere, Homology between Reaper and the cell death domains of Fas and TNFR1, Cell 81:185 (1995).
62. E. Feinstein, A. Kimchi, D. Wallach, M. Boldin, and E. Varfolomeev, The death domain: a module shared by proteins with diverse cellular functions, TIBS 20:342 (1995).
63. K. Hofman, and J. Tschopp, The death domain motif in Fas (Apo-1) and TNF receptor is present in proteins involved in apoptosis and axonal guidance, FEBS Lett. 371:321 (1995).
64. F.C. Kischkel, S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P.H. Krammer, and M.E. Peter, Cytotoxicity-dependent APO-1 (Fas/CD95)- associated proteins form a death-inducing signaling complex (DISC) with the receptor, EMBO J. 14:5579 (1995).
65. X. Su, T. Zhou, Z. Wang, P. Yang, R.S. Jope, J.D. Mountz, Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis, Immunity 2:353 (1995).
66. T. Sato, S, Irie, S. Kitada, and J.C. Reed, FAP-1: a protein tyrosine phosphatase that associates with Fas, Science 268:411 (1995).
67. R.C. Bargou, P.T. Daniel, M.Y. Mapara, K. Bommert, C. Wagener, B. Kallinich, H.D. Royer, and B. Dorken, Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-α expression in tumor cells correlates with resistance towards apoptosis, Int. J. Cancer 60:854 (1995).